{
    "nctId": "NCT05883852",
    "briefTitle": "EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer",
    "officialTitle": "A Randomized Controlled, Phase III Trial in HER2-positive Lymph Node Positive Early Breast Cancer to Compare the Efficacy and Safety of Epriubin Plus Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and Pertuzumab (EC-THP) Versus Docetaxel and Carboplatin Plus Trastuzumab and Pertuzumab (TCbHP) in the Adjuvant Treatment",
    "overallStatus": "RECRUITING",
    "conditions": "HER2 Positive Early Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 1406,
    "primaryOutcomeMeasure": "iDFS",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women aged 18-70\uff1b\n* 0-1 for ECOG\uff1b\n* Unilateral invasive carcinoma confirmed by histology (regardless of pathological type)\uff1b\n* No gross or microscopic tumor remains after surgical resection\uff1b\n* Early breast cancer, pathologically confirmed as HER2 positive; HER2 positive definition: Immunohistochemical HER2 3+ or FISH/CISH test positive (with amplification) is defined as HER2 positive\uff1b\n* Postoperative pathological stage pT1-4N1-3M0\uff1b\n* Did not receive neoadjuvant chemotherapy in the past\uff1b\n* The longest period from surgery to randomization was not more than 8 weeks, and no adjuvant therapy had been received after surgery\uff1b\n* No peripheral neuropathy\uff1b\n* Good postoperative recovery, at least 1 week interval between operation\uff1b\n* The major organs function normally, that is, meet the following criteria: (1) The standard of blood routine examination shall meet: HB \u226590 g/L (no blood transfusion within 14 days); ANC \u22651.5\u00d7109 /L; PLT \u2265100\u00d7109 /L; (2) Biochemical examination should meet the following standards: TBIL \u22641.5\u00d7ULN (upper limit of normal value); ALT and AST \u22643 x ULN; Serum Cr \u22641.5\u00d7ULN\uff1b\n* Contraception during treatment for women of reproductive age\uff1b\n* Cardiac function: LVEF\\>50% for ultrasound examination\uff1b\n* The subjects voluntarily joined the study, signed the informed consent, had good compliance, and cooperated with follow-up\u3002\n\nExclusion Criteria:\n\n* Bilateral breast cancer or carcinoma in situ DCIS/LCIS\uff1b\n* Have received chemotherapy for advanced disease\uff1b\n* Transfer of any part\uff1b\n* If any tumor \\>T4a (accompanied by skin invasion, mass adhesion fixation, inflammatory breast cancer)\uff1b\n* Patients with clinical or imaging suspicion of malignancy on the opposite breast but not confirmed, requiring biopsy\uff1b\n* Have received neoadjuvant therapy, including chemotherapy, radiotherapy and endocrine therapy\uff1b\n* Malignant neoplasms (other than basal cell carcinoma of the skin and carcinoma in situ of the cervix), including contralateral breast cancer, within the previous 5 years\uff1b\n* The patient has been enrolled in other clinical trials\uff1b\n* Patients with severe systemic disease and/or uncontrolled infection were unable to be enrolled in the study\uff1b\n* LVEF\\<50% (cardiac ultrasound)\uff1b\n* Severe cardiovascular and cerebrovascular disease (e.g., unstable angina, chronic heart failure, uncontrolled hypertension \\>150/90mmgh, myocardial infarction or cerebrovascular accident) within 6 months prior to randomization\uff1b\n* Known allergy to related drugs\uff1b\n* Women of childbearing age refuse contraception during treatment and within 8 weeks after completion of treatment\uff1b\n* Pregnant and lactating women\uff1b\n* Those who tested positive for pregnancy before taking the drug after joining the trial\uff1b\n* Mental illness, cognitive impairment, inability to understand the trial protocol and side effects, inability to complete the trial protocol and follow-up workers \uff1b(systematic evaluation is required before trial enrollment)\uff1b\n* Persons without personal freedom and independent capacity for civil conduct\u3002",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}